Biotech Values

[oc631]

This is quite a presumptuous statement by UBS if true


http://seekingalpha.com/article/277464-johnson-johnson-gilead-deal-could-yield-more-combinations-in-hiv

The timing of the deal, however, has led UBS to question whether the pharma giant [JNJ] might have seen some of Gilead's Quad data, a read out of which is widely expected in the third quarter of the this year, and made its decision based on this (Event - Gilead manufacturing subpoena could steal Quad limelight, June 13, 2011).

If this is the case, then it is unlikely the data is bad, which should bode well for both the final read out and Quad approval.